School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Arcutis Biotherapeutics, Inc. ARQT

Healthcare · Biotechnology

$26.58last close 2026-10-09 · market cap $3.34B · delayed data

Trailing returns

1M+11.49%
3M-7.64%
6M+8.18%
1Y+28.34%
5Y+18.98%

Basis: Adjusted daily closes.

What it does

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Open ARQT in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies